Top

Published in:

Open Access 01-10-2018 | Original Article

Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine

Authors: Hiroaki Shima, Goro Kutomi, Fukino Satomi, Masafumi Imamura, Yasutoshi Kimura, Toru Mizuguchi, Kazue Watanabe, Akari Takahashi, Aiko Murai, Tomohide Tsukahara, Takayuki Kanaseki, Yoshihiko Hirohashi, Yuji Iwayama, Tetsuhiro Tsuruma, Hidekazu Kameshima, Noriyuki Sato, Toshihiko Torigoe, Ichiro Takemasa

Published in: Cancer Immunology, Immunotherapy | Issue 10/2018

Abstract

A 62-year-old woman who underwent surgery to treat pancreatic cancer provided written, informed consent to undergo adjuvant therapy with gemcitabine, tegafur, and uracil. However, this was stopped after only 14 days due to Grade 4 neutropenia. She was then started on vaccine therapy with Survivin 2B peptide (SVN-2B) including IFA and INF-α. Although metastatic lung tumors were identified and resected at 82 months after surgery, the patient has remained free of new or relapsed disease for 12 years thereafter. Tetramer and ELISPOT assays revealed the continuous circulation of SVN-2B-restricted cytotoxic T-lymphocytes (CTLs) in her peripheral blood, and CTL clones had specific activity for SVN-2B at 12 years after surgery. The adverse effects of the peptide vaccination were tolerable and comprised low-grade headache, nausea, and fatigue. A prognosis beyond 10 years in the face of pancreatic cancer with distant metastasis is extremely rare. This experience might indicate the value of cancer vaccination therapy.

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915CrossRef

Pol J, Bloy N, Buqué A et al (2015) Trial watch: peptide-based anticancer vaccines. Oncoimmunology 4(4):e974411CrossRef

Tsuruma T, Hata F, Torigoe T et al (2004) Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2(1):19CrossRef

Kameshima H, Tsuruma T, Kutomi G et al (2013) Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 104:124–129CrossRef

Japan Pancreatic Society (2017) Classification of pancreatic carcinoma, 4th edn. Kanehara Pub, Tokyo, p 50 (English edn)

Tanaka T, Kitamura H, Inoue R et al (2013) Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer–results from phase I clinical trials. Clin Dev Immunol 2013:262967PubMedPubMedCentral

Kameshima H, Tsuruma T, Torigoe T et al (2011) Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci 102(6):1181–1187CrossRef

Inoda S, Hirohashi Y, Torigoe T et al (2009) Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 32(5):474–485CrossRef

Hirohashi Y, Torigoe T, Maeda A et al (2002) An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8(6):1731–1739PubMed

10.

Sato T, Sato N, Takahashi S et al (1986) Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res 46(9):4384–4389PubMed

11.

Aubry JP, Blaecke A, Lecoanet-Henchoz S et al (1999) Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37(3):197–204CrossRef

12.

Watanabe K, Suzuki S, Kamei M et al (2008) CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol 88(3):311–320CrossRef

13.

Kruger S, Haas M, Burger PJ et al (2016) Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology 16(4):593–598CrossRef

14.

Tumeh PC, Hellmann MD, Hamid O et al (2017) Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5(5):417–424CrossRef

15.

Jenne CN, Kubes P (2013) Immune surveillance by the liver. Nat Immunol 14(10):996–1006CrossRef

16.

Schmidt J, Abel U, Debus J et al (2012) Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 30(33):4077–4083CrossRef

17.

Märten A, Schmidt J, Ose J et al (2009) A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival—CapRI-2. BMC Cancer 9:160CrossRef

18.

Knaebel HP, Märten A, Schmidt J et al (2005) Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma—CapRI: study protocol [ISRCTN62866759]. BMC Cancer 5:37CrossRef

19.

Khong H, Overwijk WW (2016) Adjuvants for peptide-based cancer vaccines. J Immunother Cancer 2016; 4:56CrossRef

20.

Seya T, Shime H, Takeda Y et al (2015) Adjuvant for vaccine immunotherapy of cancer–focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci 106(12):1659–1668CrossRef

Title: Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine
Authors: Hiroaki Shima
Goro Kutomi
Fukino Satomi
Masafumi Imamura
Yasutoshi Kimura
Toru Mizuguchi
Kazue Watanabe
Akari Takahashi
Aiko Murai
Tomohide Tsukahara
Takayuki Kanaseki
Yoshihiko Hirohashi
Yuji Iwayama
Tetsuhiro Tsuruma
Hidekazu Kameshima
Noriyuki Sato
Toshihiko Torigoe
Ichiro Takemasa
Publication date: 01-10-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 10/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2217-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2018

Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells

Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study

Regulatory mechanisms of PD-L1 expression in cancer cells

Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice

Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization

3-Day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin E2 are a promising alternative for cancer immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer